SI2146961T1 - N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov - Google Patents
N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkovInfo
- Publication number
- SI2146961T1 SI2146961T1 SI200831188T SI200831188T SI2146961T1 SI 2146961 T1 SI2146961 T1 SI 2146961T1 SI 200831188 T SI200831188 T SI 200831188T SI 200831188 T SI200831188 T SI 200831188T SI 2146961 T1 SI2146961 T1 SI 2146961T1
- Authority
- SI
- Slovenia
- Prior art keywords
- oxide
- dopamine receptor
- cardiovascular side
- improved cardiovascular
- displaying improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0700893 | 2007-04-12 | ||
EP20080741904 EP2146961B1 (en) | 2007-04-12 | 2008-04-11 | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
PCT/SE2008/050414 WO2008127188A1 (en) | 2007-04-12 | 2008-04-11 | N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2146961T1 true SI2146961T1 (sl) | 2014-08-29 |
Family
ID=39864178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831188T SI2146961T1 (sl) | 2007-04-12 | 2008-04-11 | N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov |
Country Status (19)
Country | Link |
---|---|
US (1) | US9139525B2 (sl) |
EP (1) | EP2146961B1 (sl) |
JP (1) | JP5393654B2 (sl) |
CN (1) | CN101711236B (sl) |
AU (1) | AU2008239841B2 (sl) |
BR (1) | BRPI0810161A2 (sl) |
CA (1) | CA2683719C (sl) |
CY (1) | CY1115337T1 (sl) |
DK (1) | DK2146961T3 (sl) |
ES (1) | ES2458592T3 (sl) |
HR (1) | HRP20140380T1 (sl) |
IL (1) | IL201401A (sl) |
MX (1) | MX2009011020A (sl) |
NZ (1) | NZ580856A (sl) |
PL (1) | PL2146961T3 (sl) |
PT (1) | PT2146961E (sl) |
RU (1) | RU2470013C2 (sl) |
SI (1) | SI2146961T1 (sl) |
WO (1) | WO2008127188A1 (sl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
UA104152C2 (ru) | 2008-11-24 | 2014-01-10 | Интергрейтив Рисерч Лебореториз Сведен АБ | Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии |
WO2011107583A1 (en) | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
PE20160195A1 (es) | 2013-06-21 | 2016-05-14 | Teva Pharmaceuticals Int Gmbh | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington |
TW201613859A (en) * | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
WO2017147366A1 (en) | 2016-02-24 | 2017-08-31 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
CA3151507C (en) | 2016-08-24 | 2024-05-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
WO2019036358A1 (en) | 2017-08-14 | 2019-02-21 | Teva Pharmaceuticals International Gmbh | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE |
EP3675830A1 (en) | 2017-08-30 | 2020-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
CN116472043A (zh) * | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1217296A (en) | 1917-01-11 | 1917-02-27 | Lewis A Peckham | Shock-absorber. |
US2813098A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-methoxy-n-methylmorphinan n-oxide |
US2813097A (en) | 1955-08-16 | 1957-11-12 | Upjohn Co | 3-hydroxy-n-methylmorphinan-n-oxide |
US3131185A (en) | 1959-03-18 | 1964-04-28 | Orsymonde | Nicotinic esters of hydroxyl derivatives of the phenanthrenic alkaloids of opium, and process for the preparation of these esters |
BE638369A (sl) | 1962-10-10 | |||
CH481123A (de) | 1966-09-21 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von neuen, kondensierten heterocyclischen Verbindungen |
CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
AU653837B2 (en) * | 1991-04-17 | 1994-10-13 | Pharmacia & Upjohn Company | Substituted phenylazacycloalkanes as CNS agents |
JPH06509069A (ja) | 1991-06-27 | 1994-10-13 | バージニア・コモンウェルス・ユニバーシティ | シグマレセプターリガンドおよびその用途 |
IL112099A (en) * | 1993-12-23 | 1999-07-14 | Ortho Pharma Corp | N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them |
CA2144669A1 (en) | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
US6121259A (en) * | 1998-11-23 | 2000-09-19 | Sepracor Inc. | Olanzapine-N-oxide compositions and methods |
SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
SE9904723D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
SE0200301D0 (sv) * | 2002-02-01 | 2002-02-01 | Axon Biochemicals Bv | Thio-carbostyril derivative |
DE602005017784D1 (de) * | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
ATE469885T1 (de) | 2004-06-08 | 2010-06-15 | Nsab Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin- neurotransmission |
MX2007001713A (es) * | 2004-08-11 | 2007-07-13 | Donald L Barbeau | Compuestos farmaceuticos no cardiotoxicos. |
CA2584831C (en) * | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
KR20080046205A (ko) | 2005-08-22 | 2008-05-26 | 솔베이 파마슈티칼스 비. 브이 | 프로드럭으로서 피페라진 및 피페리딘 유도체의 n-산화물 |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
AU2007247251B2 (en) | 2006-05-02 | 2011-11-03 | Solvay Pharmaceuticals B.V. | N-oxides of pyridylmethylpiperazine and -piperidine derivatives |
WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
WO2011107593A1 (en) * | 2010-03-05 | 2011-09-09 | Dsm Ip Assets B.V. | Process for the production of an uhmwpe article |
MX2013002453A (es) * | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
MX2014011971A (es) * | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
WO2014052933A1 (en) * | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
EP2900226A4 (en) * | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
-
2008
- 2008-04-11 PT PT08741904T patent/PT2146961E/pt unknown
- 2008-04-11 MX MX2009011020A patent/MX2009011020A/es unknown
- 2008-04-11 CA CA2683719A patent/CA2683719C/en not_active Expired - Fee Related
- 2008-04-11 DK DK08741904T patent/DK2146961T3/da active
- 2008-04-11 EP EP20080741904 patent/EP2146961B1/en not_active Not-in-force
- 2008-04-11 CN CN2008800175988A patent/CN101711236B/zh not_active Expired - Fee Related
- 2008-04-11 SI SI200831188T patent/SI2146961T1/sl unknown
- 2008-04-11 NZ NZ580856A patent/NZ580856A/en unknown
- 2008-04-11 JP JP2010502976A patent/JP5393654B2/ja not_active Expired - Fee Related
- 2008-04-11 AU AU2008239841A patent/AU2008239841B2/en not_active Ceased
- 2008-04-11 WO PCT/SE2008/050414 patent/WO2008127188A1/en active Application Filing
- 2008-04-11 PL PL08741904T patent/PL2146961T3/pl unknown
- 2008-04-11 US US12/595,472 patent/US9139525B2/en active Active
- 2008-04-11 RU RU2009141300/04A patent/RU2470013C2/ru not_active IP Right Cessation
- 2008-04-11 BR BRPI0810161 patent/BRPI0810161A2/pt not_active IP Right Cessation
- 2008-04-11 ES ES08741904T patent/ES2458592T3/es active Active
-
2009
- 2009-10-11 IL IL201401A patent/IL201401A/en not_active IP Right Cessation
-
2014
- 2014-04-25 CY CY20141100304T patent/CY1115337T1/el unknown
- 2014-04-25 HR HRP20140380AT patent/HRP20140380T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2146961B1 (en) | 2014-01-29 |
CA2683719C (en) | 2015-07-14 |
CN101711236B (zh) | 2012-10-31 |
JP2010523651A (ja) | 2010-07-15 |
IL201401A0 (en) | 2010-05-31 |
HRP20140380T1 (hr) | 2014-08-15 |
BRPI0810161A2 (pt) | 2014-12-30 |
IL201401A (en) | 2015-10-29 |
PL2146961T3 (pl) | 2014-09-30 |
EP2146961A4 (en) | 2011-08-03 |
RU2009141300A (ru) | 2011-05-20 |
AU2008239841A1 (en) | 2008-10-23 |
ES2458592T3 (es) | 2014-05-06 |
CY1115337T1 (el) | 2017-01-04 |
PT2146961E (pt) | 2014-04-30 |
EP2146961A1 (en) | 2010-01-27 |
RU2470013C2 (ru) | 2012-12-20 |
NZ580856A (en) | 2011-11-25 |
WO2008127188A1 (en) | 2008-10-23 |
MX2009011020A (es) | 2009-10-30 |
JP5393654B2 (ja) | 2014-01-22 |
CN101711236A (zh) | 2010-05-19 |
DK2146961T3 (da) | 2014-04-28 |
US9139525B2 (en) | 2015-09-22 |
CA2683719A1 (en) | 2008-10-23 |
US20100105736A1 (en) | 2010-04-29 |
AU2008239841B2 (en) | 2013-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL201401A0 (en) | N - oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | |
IL201202A0 (en) | Imidazolidine carboxamide derivatives as p2x7 modulators | |
IL210412A0 (en) | Heterocyclic derivatives and uses thereof | |
EP2265731A4 (en) | METHODS AND COMPOSITION FOR EVALUATING MEDICATION RESPONSE | |
HK1155744A1 (en) | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | |
EP2188295A4 (en) | PYRIDINE DERIVATIVES AND METHODS OF USE | |
IL211042A0 (en) | Imidazopyridin-2-one derivatives and uses thereof | |
EP2264017A4 (en) | Heterocyclic derivative and its use | |
ZA201103635B (en) | Azaquinolinone derivatives and uses thereof | |
IL206276A0 (en) | Pyridine derivatives | |
HK1144319A1 (en) | Compositions and methods of detecting tiabs | |
HK1148283A1 (en) | Heterocyclic derivatives | |
PL2450512T3 (pl) | Zawias puszkowy | |
IL212070A (en) | Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone | |
IL213570A (en) | History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them | |
EP2081950A4 (en) | EXPRESSION PROFILES ASSOCIATED WITH IRINOTECAN TREATMENT | |
HK1135972A1 (en) | 4-substituted azaadamantane derivatives and methods of use thereof 4- | |
IL213352A0 (en) | Dihydropyridone amides as p2x7 modulators | |
IL213417A0 (en) | Dihydropyridone amides as p2x7 modulators | |
EP2344479A4 (en) | 1,2-BENZISOTHIAZOLINONE AND ISOINDOLINONE DERIVATIVES | |
EP2285778A4 (en) | NIKOTINAMIDDERIVATE | |
EP2323605A4 (en) | TRANSDERMAL RELEASE OF OLIGOSACCHARIDES | |
EP2305645A4 (en) | ARALKYLPIPERIDINE DERIVATIVES AND THEIR USES AS PAIN OR TREATMENT AGENTS | |
IL206951A0 (en) | 3-alkyl-piperazine derivatives and uses thereof | |
ZA200906572B (en) | Imidazolidine carboxamide derivatives as P2X7 modulators |